Semaglutide’s protective effects on heart and kidney health and its treatment role in combined heart-kidney problems

Semaglutide may have heart and kidney benefits in cardiorenal syndrome, but the reviewed evidence is mixed.

This comprehensive review summarizes studies linking semaglutide to slower eGFR decline, lower proteinuria, improved cardiac outcomes, and mechanisms including reduced oxidative stress, inflammation, fibrosis, apoptosis, ferroptosis, and mitochondrial dysfunction.

Some studies suggest possible renal impairment or cardiorenal syndrome progression, and the abstract calls for more animal work and large clinical trials.